ABSI - SomnoMed Limited (ASX:SOM): Fallen Angel, New Wings

 

Originally listed in 2004, SomnoMed (ASX:SOM) was once a rising name on the ASX. Although the company has endured a challenging period, it has regained momentum with new management implementing a strategic shift in the business that has strengthened both its financial performance and core operations.
 
We believe this has created a runway for the company to deliver sustained growth moving forward.

Gain Access to the Full Desk Note

 

Investor Highlights

  • Proven business with proprietary solutions – First company worldwide to provide clinically proven medical oral appliance therapy to over 1 million patients in over 20 countries globally.

  • Turnaround in progress – Consistent double-digit revenue growth (across quarterly, annual periods over pcp) and across all global jurisdictions. New management has returned the company to cash flow positive status.

  • 22% Revenue Growth YoY in FY25 to $111.5m, exceeding market guidance range of a $7m-$9m increase.

  • FY25 losses of -$0.58m, strong improvement from FY24 losses of -$13m. FY24 diluted EPS of -$0.10, improving to -$0.016 in FY25 following a pivot in operational strategy.

  • Continued penetration into global markets - Products launched further into EU territories, including national tender wins in the Nordics and the U.K. Increases in manufacturing capacity by at least 25%, set for launch in FY26 which will increase SOM’s ability to scale effectively.